Estrogen plus progestin use linked with increased breast cancer incidence and mortality
Estrogen plus progestin use is linked with increased breast cancer incidence. In addition, prognosis is similar for both users and nonusers of combined hormone therapy, suggesting that mortality from breast cancer may be higher for hormone therapy users as well, according to a study published March 29 in the Journal of the National Cancer Institute. Authors on this report included scientists from UCLA, Brigham and Women’s Hospital, Harvard, Fred Hutchinson Cancer Research Center, University of Pittsburgh, Stanford University, State University of New York, Stony Brook; University of Tennessee, University at Buffalo, University of California at Davis, University of California, Sacramento.
Among the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.